Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
05 January 2024 - 8:15AM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage
biopharmaceutical company developing a novel therapeutic that
targets toxic soluble amyloid beta oligomers for the treatment of
Alzheimer’s disease, announced today that management will present
at the 42nd Annual J.P. Morgan Healthcare Conference
taking place in San Francisco on Thursday, January 11, 2024, at
10:30 a.m. PT (1:30 p.m. ET).
The live webcast may be accessed under the
Investors tab on www.acumenpharm.com and will be archived
for 90 days.
About Acumen Pharmaceuticals,
Inc.
Acumen, headquartered in Charlottesville, VA, with
additional offices in Indianapolis, IN and Newton, MA, is a
clinical-stage biopharmaceutical company developing a novel
therapeutic that targets toxic soluble amyloid beta oligomers
(AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s
scientific founders pioneered research on AβOs, which a growing
body of evidence indicates are early and persistent triggers of
Alzheimer’s disease pathology. Acumen is currently focused on
advancing its investigational product candidate, ACU193, a
humanized monoclonal antibody that selectively targets toxic
soluble AβOs, following positive topline results in INTERCEPT-AD, a
Phase 1 clinical trial involving early Alzheimer’s disease
patients. For more information, visit www.acumenpharm.com.
Investors: Alex
Braunabraun@acumenpharm.com
Media: AcumenPR@westwicke.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Apr 2024 to May 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From May 2023 to May 2024